|
業務類別
|
Biotechnology |
|
業務概覽
|
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator ofthe alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need. |
| 公司地址
| 14 Milliston Road, Box 195, Millis, MA, USA, 02054 |
| 電話號碼
| +1 339 240-6066 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.neuphoriatx.com |
| 員工數量
| 1 |
| Mr. Timothy M. Cunningham |
Chief Financial Officer |
-- |
18/09/2026 |
| Dr. Spyros Papapetropoulos, M.D.,PhD |
Interim Chief Executive Officer and Director |
美元 284.63K |
18/09/2026 |
|
|
| Mr. Peter Miles Davies |
Independent Director |
18/09/2026 |
| Mr. Alan Fisher |
Chairman of the Board |
18/09/2026 |
| Dr. Jane Ryan, PhD |
Independent Director |
18/09/2026 |
| Mr. David Wilson |
Director |
18/09/2026 |
| Dr. Spyros Papapetropoulos, M.D.,PhD |
Interim Chief Executive Officer and Director |
18/09/2026 |
|
|
|
|